Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by losingmyshirton Sep 27, 2021 12:46pm

114 Views

Post# 33924379

Time to change the name Bob. This is not working.

Bob, abandon the R107 angle. It is obvioysly stalled and we need a new gimmick to draw in new blood and money.

Time to resurrect the old Dental Floss Ranch idea.
Millions of acres planted with dental loss. Harvesting in 2023.

Poor Bob. He needs this job and the paycheck. Give him one more chance please. He worked so hard with the Facebook page and the Kalyteran scheme when it became apparent that no news media was interested in spreading the word.\

One more chance is all he needs and mark my words, by 2025 we should see a come around.

WHAT COULD GO WRONG?

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals